The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Anteovin     (8R,9S,10R,13S,14S,17S)-13- ethyl-17...

Synonyms: Trigynon, Eugynon, Gravistat, Rigevidon, Sequostat, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Rigevidon


Psychiatry related information on Rigevidon


High impact information on Rigevidon

  • Neogynon users' performances on the Color Words Test (a measure of automatization ability) worsened and their anger, vigor and tension scores had decreased to a greater extent than was the case for members of the other groups [7].
  • FVII activity increased in both groups, achieving statistical significance (P less than 0.01) by cycle 6 in the SHD 415G group but not in the females receiving Logynon [8].
  • Ethinyl estradiol-desogestrel increased the concentration (+175%) and binding capacity (+330%) of sex hormone-binding globulin to a much greater extent than with ethinyl estradiol-levonorgestrel (+92% and +160%) [9].
  • The influence of Microgynon and Diane-35, two sub-fifty ovulation inhibitors, on voice function in women [10].
  • The pharmacokinetics of levonorgestrel (LNG) and ethinylestradiol (EE2) were determined in 9 healthy women (age 23 to 42 years), during a treatment period of three months with a low-dose oral contraceptive, containing 0.15 mg LNG together with 0.03 mg EE2 (Microgynon) [11].

Biological context of Rigevidon


Anatomical context of Rigevidon


Associations of Rigevidon with other chemical compounds

  • Lipoprotein fractions showed favourable changes in Triquilar and Marvelon users with significant rise in HDL fractions at 6 and 12 months; Microgynon 30 users had equivocal changes in HDL fractions [21].
  • Apolipoprotein A-II levels increased during Ministat treatment from 50.4 to 61.4 mg/dL and during Stediril-d 150/30 treatment from 52.7 to 58.9 mg/dL (both P less than 0.001) [22].
  • The possibility of escape ovulation in women using a fluoroquinolone ofloxacin for antibacterial treatment at a dose of 200 mg twice daily for 7 days when taking a combined oral contraceptive (Microgynon, 150 micrograms levonorgestrel and 30 micrograms ethinyl estradiol) was studied in 20 women [23].
  • The efficacy, cycle-control and tolerance of Microgynon-30, a widely prescribed levonorgestrel containing oral contraceptive, and Femodene, a new oral-contraceptive containing gestodene, were compared in a randomised, double-blind study involving 456 healthy women over a 6 month period [5].

Gene context of Rigevidon


Analytical, diagnostic and therapeutic context of Rigevidon


  1. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Mortimer, P.S., Dawber, R.P., Gales, M.A., Moore, R.A. Br. J. Dermatol. (1986) [Pubmed]
  2. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. de Abood, M., de Castillo, Z., Guerrero, F., Espino, M., Austin, K.L. Contraception. (1997) [Pubmed]
  3. The relationship between vascular headaches and low-dose oral contraceptives. Karsay, K. Therapia Hungarica (English edition) (1990) [Pubmed]
  4. SHBG, testosterone, androstenedione, 17-OH-Progesterone plasma levels in PCO affected women treated with a triphasic oral contraceptive. Negri, P., Agnello, G., Borghesani, F., Tomain, L., Minisci, N., D'Errico, G., Cavallini, A.R. Acta Eur. Fertil. (1987) [Pubmed]
  5. A double-blind comparison of the efficacy and acceptability of Femodene and Microgynon-30. Loudon, N.B., Kirkman, R.J., Dewsbury, J.A. Eur. J. Obstet. Gynecol. Reprod. Biol. (1990) [Pubmed]
  6. Comparison of a paper pill with a conventional oral contraceptive tablet. Basu, H.K., Edwards, C. J. Int. Med. Res. (1980) [Pubmed]
  7. A prospective study of the effects of the progestagen content of oral contraceptives on measures of affect, automatization, and perceptual restructuring ability. Worsley, A. Psychopharmacology (Berl.) (1980) [Pubmed]
  8. A comparison of the effects of two triphasic oral contraceptives on haemostasis. Cohen, H., Mackie, I.J., Walshe, K., Gillmer, M.D., Machin, S.J. Br. J. Haematol. (1988) [Pubmed]
  9. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Jung-Hoffmann, C., Kuhl, H. Am. J. Obstet. Gynecol. (1987) [Pubmed]
  10. The influence of Microgynon and Diane-35, two sub-fifty ovulation inhibitors, on voice function in women. Wendler, J., Siegert, C., Schelhorn, P., Klinger, G., Gurr, S., Kaufmann, J., Aydinlik, S., Braunschweig, T. Contraception. (1995) [Pubmed]
  11. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. Kuhnz, W., al-Yacoub, G., Fuhrmeister, A. Contraception. (1992) [Pubmed]
  12. Metabolic effects of the triphasic oral contraceptive Trigynon. Vermeulen, A., Thiery, M. Contraception. (1982) [Pubmed]
  13. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis. Smith, S.K., Kirkman, R.J., Arce, B.B., McNeilly, A.S., Loudon, N.B., Baird, D.T. Contraception. (1986) [Pubmed]
  14. Results of a multilateral study with Anteovin. Seregély, G. Therapia Hungarica (English edition) (1990) [Pubmed]
  15. The effects of menstruation and Microgynon 30 on sway behaviour. Graham, S.E., Thornton, H., Atha, J. Agressologie (1978) [Pubmed]
  16. Effects of oral contraceptive pills on serum lipoproteins and triglycerides. Towobola, O.A., Otubu, J.A., Uguru, V.E. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. (1990) [Pubmed]
  17. Up-regulatory effect of triphasic oral contraceptive on platelet 3H-imipramine binding sites. Weizman, A., Morgenstern, H., Kaplan, B., Amiri, Z., Tyano, S., Ovadia, Y., Rehavi, M. Psychiatry research. (1988) [Pubmed]
  18. Oral contraceptives and their influence on porphyrin concentrations in erythrocytes and urine. Kansky, A., Gregorc, J., Pavlic, M. Dermatologica (1978) [Pubmed]
  19. Examination of the effect of Anteovin tablet on the endometrium. Farkas, M., Farkas, E., Sas, M. Therapia Hungarica (English edition) (1985) [Pubmed]
  20. Changes of activities of some transferases, alkaline phosphatase and cholinesterase in the blood of women using oral contraceptives and in vitro influence of these agents on tissular enzyme levels in rat liver. Calić, R., Straus, B., Cepelak, I. Zeitschrift für medizinische Laboratoriumsdiagnostik. (1989) [Pubmed]
  21. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women. Prasad, R.N., Liew, D., Ratnam, S.S. Contraception. (1989) [Pubmed]
  22. Effect of low-dose oral contraceptives on lipoproteins and lipolytic enzymes: differences between two commonly used preparations. Leuven, J.A., Havekes, L., van der Kooij-Pontier, H.A., Starmans, R.J., Jansen, H., Bouwhuis-Hoogerwerf, M.L., de Pagter, H.A., Hessel, L.W. Metab. Clin. Exp. (1984) [Pubmed]
  23. Risk for ovulation in women taking a low-dose oral contraceptive (Microgynon) when receiving antibacterial treatment with a fluoroquinolone (ofloxacin). Csemiczky, G., Alvendal, C., Landgren, B.M. Advances in contraception : the official journal of the Society for the Advancement of Contraception. (1996) [Pubmed]
  24. Changes in blood levels of proteinase inhibitors, pregnancy zone protein, steroid carriers and complement factors induced by oral contraceptives. Nielsen, C.H., Poulsen, H.K., Teisner, B., Thorsen, P., Hau, J., Westergaard, J.G. Eur. J. Obstet. Gynecol. Reprod. Biol. (1993) [Pubmed]
  25. Action of hormonal contraceptives on the coagulation system and some of its inhibitors. Misz, M., Beck, P. Acta medica Hungarica. (1986) [Pubmed]
  26. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Bjarnadóttir, R.I., Tuppurainen, M., Killick, S.R. Am. J. Obstet. Gynecol. (2002) [Pubmed]
  27. A randomized double-blind trial of two low dose combined oral contraceptives. Bounds, W., Vessey, M., Wiggins, P. British journal of obstetrics and gynaecology. (1979) [Pubmed]
  28. Does gonadotropin suppression result in follicular development in premature ovarian failure? Buckler, H.M., Healy, D.L., Burger, H.G. Gynecol. Endocrinol. (1993) [Pubmed]
WikiGenes - Universities